FDA Advisory Panel To Evaluate Acetaminophen Pediatric Dosing
This article was originally published in The Tan Sheet
Executive Summary
FDA's pediatric and nonprescription drugs advisory committees will consider whether the agency should add dosing information for children under 2 years to labels for OTC products containing acetaminophen at a joint meeting May 17-18.
You may also be interested in...
Acetaminophen Panel To Mull Expanded Dosing, Standard Solid Concentration
FDA is asking a joint advisory panel to consider whether it should restrict firms to one standard acetaminophen concentration for all solid oral dosage single-ingredient pediatric products, among other measures to reduce dosing errors.
Lower Acetaminophen Doses Recommended Despite Cost Impact, Lack Of Data
A joint advisory committee recommended as a "top priority" that FDA lower the maximum single and daily dose of acetaminophen, despite inconclusive data that the current dose poses significant hepatotoxicity risks
Pediatric Acetaminophen Expanded Dosing Requested In McNeil Petition
Expanded dosing directions in the labeling of pediatric acetaminophen products to include children under two is requested by McNeil Consumer Healthcare in a citizen petition filed with FDA Feb. 1.